151 related articles for article (PubMed ID: 37769252)
21. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
[TBL] [Abstract][Full Text] [Related]
22. An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study.
Shehadeh K; Levinsky Y; Kagan S; Zuabi T; Tal R; Aviran NH; Butbul Aviel Y; Tirosh I; Spielman S; Miller-Barmak A; Semo Oz R; Harel L; Chodick G; Amarilyo G
Int Immunopharmacol; 2024 May; 132():111967. PubMed ID: 38569431
[TBL] [Abstract][Full Text] [Related]
23. Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients.
Akar S; Cetin P; Kalyoncu U; Karadag O; Sari I; Cınar M; Yilmaz S; Onat AM; Kisacik B; Erden A; Balkarli A; Kucuksahin O; Oner SY; Senel S; Tufan A; Direskeneli H; Oksuz F; Pehlivan Y; Bayindir O; Keser G; Aksu K; Omma A; Kasifoglu T; Unal AU; Yildiz F; Balci MA; Yavuz S; Erten S; Ozgen M; Sayarlıoglu M; Dogru A; Yildirim G; Oner FA; Tezcan ME; Pamuk ON; Onen F
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1090-1094. PubMed ID: 28992387
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
Atas N; Eroglu GA; Sodan HN; Ozturk BO; Babaoglu H; Satis H; Karadeniz H; Guler AA; Salman RB; Goker B; Ozturk MA; Haznedaroglu S; Tufan A
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):30-36. PubMed ID: 34251317
[TBL] [Abstract][Full Text] [Related]
25. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
Eren Akarcan S; Dogantan S; Edeer Karaca N; Aksu G; Kutukculer N
Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456
[TBL] [Abstract][Full Text] [Related]
26. Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF.
Pinchevski-Kadir S; Gerstein M; Pleniceanu O; Yacobi Y; Vivante A; Granat OE; Spielman S; Oz RS; Tirosh I
Pediatr Rheumatol Online J; 2023 Jan; 21(1):4. PubMed ID: 36624531
[TBL] [Abstract][Full Text] [Related]
27. A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.
Kuemmerle-Deschner JB; Gautam R; George AT; Raza S; Lomax KG; Hur P
Rheumatology (Oxford); 2020 Oct; 59(10):2711-2724. PubMed ID: 32533192
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.
Tomokawa T; Koga T; Endo Y; Michitsuji T; Kawakami A
Mod Rheumatol; 2022 Jul; 32(4):797-802. PubMed ID: 34897516
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of biologic treatments in Familial Mediterranean Fever.
Akgul O; Kilic E; Kilic G; Ozgocmen S
Am J Med Sci; 2013 Aug; 346(2):137-41. PubMed ID: 23276893
[TBL] [Abstract][Full Text] [Related]
30. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G; Jawad A; Uthman I
Orphanet J Rare Dis; 2019 Oct; 14(1):224. PubMed ID: 31615541
[TBL] [Abstract][Full Text] [Related]
31. Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine.
Berdeli A; Şenol Ö; Talay G
Eur J Rheumatol; 2019 Apr; 6(2):85-88. PubMed ID: 31365342
[TBL] [Abstract][Full Text] [Related]
32. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients.
Başaran Ö; Uncu N; Çelikel BA; Taktak A; Gür G; Cakar N
Mod Rheumatol; 2015 Jul; 25(4):621-4. PubMed ID: 25528863
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
Sendogan DO; Saritas H; Kumru G; Eyupoglu S; Sadioglu RE; Tuzuner A; Sengul S; Keven K
Transplant Proc; 2019 Sep; 51(7):2292-2294. PubMed ID: 31400972
[TBL] [Abstract][Full Text] [Related]
35. Could tocilizumab be used in familial Mediterranean Fever? A systematic review.
Mertz P; Hentgen V; Georgin-Lavialle S
Rheumatology (Oxford); 2024 Jul; ():. PubMed ID: 38950176
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis.
Ozdogan H; Ugurlu S; Uygunoglu U; Tutuncu M; Gul A; Akman G; Siva A
Mult Scler Relat Disord; 2020 Oct; 45():102332. PubMed ID: 32645635
[TBL] [Abstract][Full Text] [Related]
37. IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations.
Kharouf F; Tsemach-Toren T; Ben-Chetrit E
Clin Exp Rheumatol; 2022 Sep; 40(8):1567-1574. PubMed ID: 36062765
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases.
Yücel BB; Aydog O; Nalcacioglu H; Yılmaz A
Front Pediatr; 2021; 9():710501. PubMed ID: 34568239
[TBL] [Abstract][Full Text] [Related]
39. Total Hip Joint Replacement in a Patient with Colchicine-Resistant Familial Mediterranean Fever under Canakinumab Treatment.
Matsumoto H; Ohashi H; Fujita Y; Yoshida S; Yokose K; Temmoku J; Matsuoka N; Shinden Y; Kusano K; Sonobe T; Nakamoto Y; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Feb; 256(2):169-174. PubMed ID: 35236806
[TBL] [Abstract][Full Text] [Related]
40. Interventions for reducing inflammation in familial Mediterranean fever.
Wu B; Xu T; Li Y; Yin X
Cochrane Database Syst Rev; 2015 Mar; (3):CD010893. PubMed ID: 25791871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
